Characteristics of multicentres, randomized, double-blind, placebo-controlled studies included in the meta-analysis.

<p>Characteristics of multicentres, randomized, double-blind, placebo-controlled studies included in the meta-analysis.</p

Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis

<div><p>Background</p><p>Although efficacy of venlafaxine extended release (XR) for generalized anxiety disorder (GAD) has been reported in previous analyses in 2002 and 2004, the sample size was rather small and estimate of safety or tolerability was not clear. The present analysis had the advantage of large sample size and provided evidence for tolerability.</p><p>Methods</p><p>Literature databases were searched, including Pubmed, Embase, Cochrane Central Register of Controlled Trials, Web of science and clinical trials. 10 eligible articles were finally selected and data was extracted and logged into the Review Manager 5.3 by two independent authors. The risk of bias was evaluated by the Cochrane Collaboration’s Risk of Bias Tool and the stability of the results was assessed by sensitivity analysis. The publication bias was assessed by funnel plot and Egger’s/Begg’s test using Stata Version 12.0 software.</p><p>Results</p><p>In the current meta-analysis, 10 articles (14 studies) satisfying the inclusion criteria were analyzed. As efficacy outcomes, our findings indicated venlafaxine XR was significantly more effective than placebo according to mean change of the Hamilton Rating Scale for Anxiety total scores [mean difference = 3.31, 95% confidence interval(CI) 1.44–5.18, P = 0.0005], response [odds ratio(OR) = 1.83, 95%CI 1.58–2.12, P<0.00001], and remission (OR = 2.55, 95%CI 1.36–4.78, P = 0.003). In terms of tolerability, the most frequently reported treatment-emergent adverse events were nausea, dry mouth, dizziness, insomnia, somnolence, and headache. In addition, discontinuation due to all-cause (OR = 1.17, 95%CI 0.92–1.49, P = 0.19) was not significantly different between the two groups, whereas discontinuation due to adverse events was statistically higher in the venlafaxine XR group compared with the placebo treatment (OR = 2.80, 95%CI 2.21–3.54, P<0.00001) and discontinuation due to inefficacy was lower in venlafaxine than placebo treatment (OR = 0.26, 95%CI 0.17–0.40, P<0.00001). There was no significant publication bias and sensitivity analysis showed that our analysis exhibited high stability.</p><p>Conclusion</p><p>We concluded that venlafaxine XR (75–225 mg/day) is an effective and well-tolerated pharmacological treatment option for adult patients with GAD.</p></div

Funnel plot of publication bias.

<p>Funnel plot of publication bias.</p

A risk of bias gragh, B risk of bias summary(“+”low risk;“?”, unclear risk;“-”,high risk).

<p>A risk of bias gragh, B risk of bias summary(“+”low risk;“?”, unclear risk;“-”,high risk).</p

Forest plots of primary and secondary efficacy outcomes.

<p>SD, standard deviation; CI, confidence interval; M-H, Mantel-Haenszel.</p

Forest plots of discontinuation due to any reason, AEs, and lack of efficacy.

<p>AEs, adverse effects; SD, standard deviation; CI, confidence interval; M-H, Mantel-Haenszel.</p

Table_1_Research landscape and trends of cerebral amyloid angiopathy: a 25-year scientometric analysis.DOCX

BackgroundCerebral amyloid angiopathy (CAA), a cerebral small vessel disease affecting leptomeningeal and cortical small blood vessels, is a common cause of spontaneous lobar intracerebral hemorrhage and cognitive impairment, particularly in elderly patients. This study aims to investigate the field of CAA research from a scientometric perspective.MethodsPublications related to CAA from January 1st, 1999 to September 29th, 2023 were retrieved from the Web of Science Core Collection database. The scientometric software VOSviewer and CiteSpace were used to analyze and visualize the publication trends, countries/regions, institutions, authors, journals, cited references, and keywords of CAA.ResultsA total of 2,798 publications related to CAA from 73 countries/regions, led by the United States, were included. The number of publications showed an increasing trend over time. Massachusetts General Hospital was the most productive institution, and authors Greenberg and Charidimou published the most papers and were most frequently co-cited. Journal of Alzheimer's Disease was the most prolific journal in this field, and Neurology was the most co-cited journal. Apart from “cerebral amyloid angiopathy”, the most frequently used keywords were “Alzheimer's disease”, “amyloid beta”, “intracerebral hemorrhage”, and “dementia”. The burst keywords in recent years included “cortical superficial siderosis” and “dysfunction”.ConclusionsThis scientometric analysis provides a comprehensive overview of CAA research over the past 25 years, and offers important insights for future research directions and scientific decision-making in this field.</p

Meta-analysis of the most frequent TEAEs with a frequency of≥5% in duloxetine-treated patients.

<p>Meta-analysis of the most frequent TEAEs with a frequency of≥5% in duloxetine-treated patients.</p

Forest plots of HAM-A psychic and somatic anxiety factor scores.

<p>(A) Baseline psychic anxiety factor score. (B) Baseline somatic anxiety factor score.</p

Forest plots of HADS anxiety subscale score.

<p>(A) Baseline. (B) Mean change with treatment.</p